Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00090324 · ClinicalTrials.gov registry record · Phase 3
Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Adolescent Patients With Schizophrenia
A Phase 3 study of Schizophrenia, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 249
- Enrollment target
- 20
- Study locations
NCT00090324 is a Phase 3 study of Schizophrenia that has completed, run by AstraZeneca. The registered enrollment target is 249 participants, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (14% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT00090324, a Phase 3 study of Schizophrenia, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 249 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to demonstrate efficacy and safety of quetiapine fumarate (SEROQUEL) compared with placebo in the treatment of adolescent patients with schizophrenia.
Conditions Studied
Interventions
- DRUG quetiapine fumarate tablets
Study Locations (20)
California
- Research Site - Cerritos
- Research Site - Riverside
- Research Site - Sacramento
- Research Site - San Diego
Florida
- Research Site - Alamonte
- Research Site - Jacksonville
- Research Site - Miami
Ohio
- Research Site - Cincinnati
- Research Site - Cleveland
- Research Site - Lyndhurst
Illinois
- Research Site - Chicago
- Research Site - Oak Brook
Alabama
- Research Site - Dothan
Colorado
- Research Site - Denver
Kansas
- Research Site - Newton
Louisiana
- Research Site - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 249 participants |
| Start Date | 2004-09 |
| Est. Completion | 2007-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00090324
The ClinicalTrials.gov registry entry for NCT00090324 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 249 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (14% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which quetiapine fumarate tablets is the first listed.
NCT00090324 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT00090324 about?
NCT00090324 is a clinical study titled "Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Adolescent Patients With Schizophrenia". The purpose of this study is to demonstrate efficacy and safety of quetiapine fumarate (SEROQUEL) compared with placebo in the treatment of adolescent patients with schizophrenia.
What is the current status of trial NCT00090324?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 249 participants. The study started on 2004-09. Estimated completion is 2007-06.
What conditions does trial NCT00090324 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT00090324?
The interventions under investigation include: quetiapine fumarate tablets (DRUG).
Who is sponsoring clinical trial NCT00090324?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00090324 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
-
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
RECRUITING · Phase 3
-
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
RECRUITING · Phase 3
-
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
RECRUITING · Phase 3
-
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.